Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation.
about
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsIn vitro and in vivo modifications of recombinant and human IgG antibodiesAlloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicityCell Surface and Membrane Engineering: Emerging Technologies and ApplicationsFc-fusion technology and recombinant FVIII and FIX in the management of the hemophiliasGlycan analysis of therapeutic glycoproteinsMolecular farming on rescue of pharma industry for next generations.N-Glycan Modification of a Recombinant Protein via Coexpression of Human Glycosyltransferases in Silkworm Pupae.Feeder & basic fibroblast growth factor-free culture of human embryonic stem cells: Role of conditioned medium from immortalized human feeders.In-depth method for the characterization of glycosylation in manufactured recombinant monoclonal antibody drugsChemical synthesis of the β-subunit of human luteinizing (hLH) and chorionic gonadotropin (hCG) glycoprotein hormonesGanglioside biochemistryOverview of the purification of recombinant proteins.Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.Comprehensive Glycomics of a Multistep Human Brain Tumor Model Reveals Specific Glycosylation Patterns Related to MalignancyAnalytical detection and characterization of biopharmaceutical glycosylation by MS.Hijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteinsAt least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibodyIn-depth characterization of N-linked oligosaccharides using fluoride-mediated negative ion microfluidic chip LC-MSCharacterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).The use of lectin microarray for assessing glycosylation of therapeutic proteins.Preferential lectin binding of cancer cells upon sialic acid treatment under nutrient deprivationAdvances in Mammalian cell line development technologies for recombinant protein production.The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth.Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.Involvement of a non-human sialic Acid in human cancer.GeneOptimizer program-assisted cDNA reengineering enhances sRAGE autologous expression in Chinese hamster ovary cells.Matrix attachment region combinations increase transgene expression in transfected Chinese hamster ovary cellsDevelopment of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.Industrial production of clotting factors: Challenges of expression, and choice of host cells.The nutritional role of free sialic acid, a human milk monosaccharide, and its application as a functional food ingredient.Using glyco-engineering to produce therapeutic proteins.The present state of the art in expression, production and characterization of monoclonal antibodies.An automated data-driven DSP development approach for glycoproteins from yeast.A BioDesign Approach to Obtain High Yields of Biosimilars by Anti-apoptotic Cell Engineering: a Case Study to Increase the Production Yield of Anti-TNF Alpha Producing Recombinant CHO Cells.New Mammalian Expression Systems.Baby hamster kidney cell-derived recombinant factor VIII: a quarter century of learning and clinical experience.Approaches for recombinant human factor IX production in serum-free suspension cultures.Improving expression of recombinant human IGF-1 using IGF-1R knockout CHO cell lines.
P2860
Q26822421-90DC5E02-1605-4346-955E-28EEB6FCECCEQ26859713-02D98D03-A2A5-4DCF-A1EB-B6943F22307DQ26866323-97EBEFC5-A5DD-4C0A-9AE7-37378860BE11Q26866558-74D1CDD4-BF06-496C-9FD5-5DB712B5E1DEQ27014771-92F53834-0D9C-41E7-813E-737E6AF6C581Q28082842-3ACC6D76-F33D-4933-910D-26CF2DA2A0DEQ30252148-40AE5F2F-BC4A-46D0-B17E-6AEF0F0B34A6Q33684020-32B80AD9-9AA1-4B58-817D-81F4846D83CBQ33692339-C7BBCE46-A5A7-413B-8972-3CB9E09D8416Q33791817-61618764-A2C2-48AA-A4F8-E940B4363344Q34489536-2D674AD1-C283-4A03-8B00-505ECA34CB4DQ35361488-079762A2-7E8D-4053-9DD1-11EAF9815BDDQ35541296-44F678C6-4E2A-4F50-9459-4799C334FD4CQ35565320-6E5B29CC-1E1F-4C40-85B1-1F61EDA6A47FQ35679876-E7153343-56DF-49CC-BD2B-EB43CFC1178AQ35953047-41F03C57-BADE-4D37-87AD-F2AC984983ADQ36496166-40433307-D7C6-41E2-863F-4198986C9D8AQ36517187-F7259D02-88AA-45BC-A35B-274556F0F391Q36704033-C38ADAA5-011C-4BA8-A870-A0068DD5D432Q37138255-010F8C43-9E37-460F-86EE-F401A7E1B790Q37138938-97FCDE42-1C91-445E-B8B3-E3239362DB7AQ37269017-A9D8752D-86C5-4E04-BBD5-123B9D718374Q37280293-6B05D2D1-F579-4149-96AA-7D11D1B4AAACQ37355646-76B1CD4A-DE6C-4F1F-8E28-CE27B0CADB19Q37494846-9A3434C6-715B-421D-A856-49F3A8E52E90Q37592596-10F63997-89B8-42B7-8973-E44581356A2DQ37607192-24A2412F-C7C7-4853-81EA-E09BF2B803ACQ37652229-2146FEA7-E490-44CF-8A5E-E661A635014BQ38127745-C4F8A4CC-6670-43E2-B6F9-5040E623AF8FQ38212929-D2804FF8-F99D-401C-BC9A-F057AAE865CEQ38534584-4D793E38-33FF-4C21-93E2-EF8A2ED5594EQ38538651-F48E5F85-2124-4C99-9E62-AE2B1438FE50Q38547311-F460A208-7E58-413B-AA95-08EFE86AED9CQ38572163-5BD22729-E90A-46DE-8401-270921779971Q38641433-3C5816CD-0B3E-4E08-A330-316DE12F0FECQ38697887-9AB3D8F3-7FB9-4C9A-A813-1E6527033E48Q38701179-7E1FE7A6-C289-4704-97AE-96954F04AEDFQ38731189-13DFD856-00FE-4AA4-B9D1-B114EE1B97D1Q38819734-CDF0BA55-7EFD-4B04-8CE7-3884EEEDBBC5Q38823009-9F68E755-7B37-45D4-86E4-065D5FC5256B
P2860
Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Production platforms for bioth ...... nges of non-human sialylation.
@en
type
label
Production platforms for bioth ...... nges of non-human sialylation.
@en
prefLabel
Production platforms for bioth ...... nges of non-human sialylation.
@en
P2093
P2860
P356
P1476
Production platforms for bioth ...... nges of non-human sialylation.
@en
P2093
Ajit Varki
Darius Ghaderi
Nancy Hurtado-Ziola
P2860
P304
P356
10.5661/BGER-28-147
P577
2012-01-01T00:00:00Z